{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BBLGW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BBLGW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBLGW\",,,,,undefined,":{"symbol":"BBLGW","market":"US","secType":"STK","nameCN":"Bone Biologics Corp","latestPrice":43.95,"timestamp":1746216000000,"preClose":43.95,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Pre-Mkt","change":0,"latestTime":"05-05 07:00:37 EDT","open":43.95,"high":43.95,"low":43.95,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":3.15,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746451800000},"marketStatusCode":1,"adr":0,"listingDate":1634097600000,"exchange":"NASDAQ","adjPreClose":43.95,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBLGW\",,,,,undefined,":{"symbol":"BBLGW","floatShares":0,"roa":"-69.40%","roe":"-128.71%","lyrEps":0,"shares":0,"dividePrice":0,"high":43.95,"amplitude":0,"preClose":43.95,"low":43.95,"week52Low":3,"pbRate":"0.00","week52High":95.04,"institutionHeld":0,"latestPrice":43.95,"committee":1,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":43.95,"prevYearClose":40,"prevWeekClose":43.95,"prevMonthClose":43.95,"prevQuarterClose":20.2,"fiveDayClose":43.95,"twentyDayClose":20.2,"sixtyDayClose":89.77},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBLGW\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514824643","title":"BBLG Continues Crucial Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2514824643","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514824643?lang=en_us&edition=fundamental","pubTime":"2025-02-27 19:17","pubTimestamp":1740655020,"startTime":"0","endTime":"0","summary":"Bone Biologics  announced the company’s full year 2024 financial results and while a company at this stage is far more reliant on testing of products, which is discussed below and advancing rapidly, the financial picture is also vital. This year’s release shows that the company has made further advances in controlling expenses and diligently working on cutting anything not directly related to getting NB1 to the commercialization stage. The company’s cash balance is solid at just over $3.3 million at the end of the fourth quarter, while borrowing by the company remains nonexistent. The company noted that it currently has enough cash on hand to finance operations through 4Q2025, which puts them in a comparatively healthy situation for a clinical stage company. Additionally, as we look to the current year, we are looking forward to hearing more updates on the testing described below of this very promising treatment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bblg-continues-crucial-testing-111700918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4185","BK4585","TLIF","BBLG","BK4546","DDD","BK4170","BK4551","BBLGW","BK4161","BK4588","BK4139"],"gpt_icon":1},{"id":"2483719309","title":"BBLG in Good Shape as Testing Continues","url":"https://stock-news.laohu8.com/highlight/detail?id=2483719309","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483719309?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:03","pubTimestamp":1731668580,"startTime":"0","endTime":"0","summary":"Bone Biologics  announced the company’s 3Q 2024 financial results and while a company at this stage is far more reliant on testing of products, which is discussed below and advancing nicely, the financial picture is also vital. This quarter’s release shows that the company has made further advances in controlling expenses and diligently working on cutting anything not directly related to getting NB1 to the commercialization stage. The company’s cash balance is solid at just over $3.5 million at the end of the quarter, while borrowing by the company remains nonexistent. The company noted that it currently has enough cash on hand to finance operations through 2Q2025, which puts them in a comparatively healthy situation for a clinical stage company. Additionally, as we look forward to 2025, we are looking forward to hearing more updates on the testing described below of this very promising treatment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bblg-good-shape-testing-continues-110300226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","TLIF","BK4161","BBLGW","BK4170","BK4585","BK4551","BK4185","DDD","BBLG","BK4139","BK4546"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBLGW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2023-06-07","symbol":"BBLGW","defaultRemindTime":1686144600000,"type":"split","dateTimestamp":1686110400000,"forFactor":30,"toFactor":1,"ratio":30}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBLGW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBLGW\",market:\"US\",delay:false,,,undefined,":{}}}